4.6 Article

BRAF V600E Is a Determinant of Sensitivity to Proteasome Inhibitors

期刊

MOLECULAR CANCER THERAPEUTICS
卷 12, 期 12, 页码 2950-2961

出版社

AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1535-7163.MCT-13-0243

关键词

-

类别

资金

  1. Fondazione Piemontese per la Ricerca sul Cancro ONLUS grant 'Farmacogenomica - 5 per mille 2009 MIUR'
  2. AIRC [MFAG 11349, 9970]
  3. European Community [259015 COLTHERES]
  4. Fondazione Piemontese per la Ricerca sul Cancro ONLUS (MIUR)
  5. Fondazione Umberto Veronesi - Young Investigator Programme

向作者/读者索取更多资源

A critical step toward defining tailored therapy in patients with cancer is the identification of genetic interactions that may impair- or boost-the efficacy of selected therapeutic approaches. Cell models able to recapitulate combinations of genetic aberrations are important to find drug-genotype interactions poorly affected by the heterogeneous genetics of human tumors. In order to identify novel pharmacogenomic relationships, we employed an isogenic cell panel that reconstructs cancer genetic scenarios. We screened a library of 43 compounds in human hTERT-HME1 epithelial cells in which PTEN or RB1 were silenced in combination with the targeted knockin of cancer-associated mutations in EGFR, KRAS, BRAF, or PIK3CA oncogenes. Statistical analysis and clustering algorithms were applied to display similar drug response profiles and mutation-specific patterns of activity. From the screen, we discovered that proteasome inhibitors show selectivity toward BRAF V600E-mutant cells, irrespective of PTEN or RB1 expression. Preferential targeting of BRAF-mutant cells by proteasome inhibitors was corroborated in a second BRAF V600E isogenic model, as well as in a panel of colorectal cancer cell lines by the use of the proteasome inhibitor carfilzomib. Notably, carfilzomib also showed striking in vivo activity in a BRAF-mutant human colorectal cancer xenograft model. Vulnerability to proteasome inhibitors is dependent on persistent BRAF signaling, because BRAF V600E blockade by PLX4720 reversed sensitivity to carfilzomib in BRAF-mutant colorectal cancer cells. Our findings indicated that proteasome inhibition might represent a valuable targeting strategy in BRAF V600E-mutant colorectal tumors. (C)2013 AACR.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据